CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited) - USD ($)	Total	Cumulative Effect, Period of Adoption, Adjustment	Common Stock	Additional Paid-in Capital	Retained Earnings
Beginning balance (in shares) at Mar. 31, 2019			9,284,118
Beginning balances at Mar. 31, 2019	$ 552,116,625			$ 198,125,649	$ 353,990,976
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Proceeds from exercise of stock options (in shares)			69,181
Proceeds from exercise of stock options	4,589,974
Stock Repurchased and Retired During Period (in shares)			(1,392,180)
Stock Repurchased and Retired During Period, Value	(190,010,912)				(190,010,912)
Restricted common stock expense under stock option plan (in shares)			(29,106)
Issuance of restricted common stock under stock option plan	14,062,985			14,062,985
Stock option expense	4,394,143			4,394,143
Net income (loss)	4,853,989				4,853,989
Ending balances at Dec. 31, 2019	390,006,804			221,172,751	168,834,053
Ending balance (in shares) at Dec. 31, 2019			7,932,013
Beginning balance (in shares) at Mar. 31, 2019			9,284,118
Beginning balances at Mar. 31, 2019	$ 552,116,625			198,125,649	353,990,976
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201605Member
Ending balances at Mar. 31, 2020	$ 411,963,067	$ (21,242,249)		227,214,577	184,748,490
Ending balance (in shares) at Mar. 31, 2020			7,807,834
Beginning balance (in shares) at Sep. 30, 2019			7,945,842
Beginning balances at Sep. 30, 2019	393,237,210			218,135,573	175,101,637
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Proceeds from exercise of stock options (in shares)			13,709
Proceeds from exercise of stock options	935,877			935,877
Stock Repurchased and Retired During Period (in shares)			0
Stock Repurchased and Retired During Period, Value	0				0
Restricted common stock expense under stock option plan (in shares)			(27,538)
Issuance of restricted common stock under stock option plan	933,268			933,268
Stock option expense	1,168,033			1,168,033
Net income (loss)	(6,267,584)				(6,267,584)
Ending balances at Dec. 31, 2019	390,006,804			221,172,751	168,834,053
Ending balance (in shares) at Dec. 31, 2019			7,932,013
Beginning balance (in shares) at Mar. 31, 2020			7,807,834
Beginning balances at Mar. 31, 2020	411,963,067	$ (21,242,249)		227,214,577	184,748,490
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Proceeds from exercise of stock options (in shares)			33,776
Proceeds from exercise of stock options	2,255,824
Stock Repurchased and Retired During Period (in shares)			(1,024,870)
Stock Repurchased and Retired During Period, Value	(88,848,296)				(88,848,296)
Restricted common stock expense under stock option plan (in shares)			(50,962)
Issuance of restricted common stock under stock option plan	8,347,347			8,347,347
Stock option expense	$ 2,987,621			2,987,621
Accounting Standards Update [Extensible List]	us-gaap:AccountingStandardsUpdate201613Member
Net income (loss)	$ 43,398,875				43,398,875
Ending balances at Dec. 31, 2020	358,862,189			240,805,369	118,056,820
Ending balance (in shares) at Dec. 31, 2020			6,765,778
Beginning balance (in shares) at Sep. 30, 2020			7,002,080
Beginning balances at Sep. 30, 2020	367,275,151			237,547,566	129,727,585
Increase (Decrease) in Shareholders' Equity [Roll Forward]
Proceeds from exercise of stock options (in shares)			18,205
Proceeds from exercise of stock options	1,248,999			1,248,999
Stock Repurchased and Retired During Period (in shares)			(238,452)
Stock Repurchased and Retired During Period, Value	(26,161,371)				(26,161,371)
Restricted common stock expense under stock option plan (in shares)			(16,055)
Issuance of restricted common stock under stock option plan	1,154,157			1,154,157
Stock option expense	854,647			854,647
Net income (loss)	14,490,606				14,490,606
Ending balances at Dec. 31, 2020	$ 358,862,189			$ 240,805,369	$ 118,056,820
Ending balance (in shares) at Dec. 31, 2020			6,765,778